Mallinckrodt Presents TERLIVAZ® Data for Hepatorenal Syndrome at DDW 2024

Facebook
Pinterest
Twitter
LinkedIn

Mallinckrodt plc, a global specialty pharmaceutical company, recently presented two posters at the 2024 Digestive Disease Week® (DDW) in Washington, DC, highlighting the efficacy of TERLIVAZ® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) experiencing rapid reduction in kidney function1.

The posters, presented from May 18-21, 2024, shed light on the potential of TERLIVAZ® as a treatment option for HRS patients. Hepatorenal syndrome is a severe and life-threatening condition that affects individuals with advanced liver disease, leading to rapid deterioration of kidney function.

The data presented at DDW 2024 underscores Mallinckrodt’s commitment to developing innovative therapies for patients with critical conditions such as HRS. The company continues to invest in research and development to improve patient outcomes and address unmet medical needs in the field of gastroenterology and hepatology.